Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In cystic fibrosis (CF) the defective CF transmembrane conductance regulator protein may be responsible for the impaired transport of glutathione (GSH), the first line defense of the lung against oxidative stress. The aim of this single-blind, randomized, placebo-controlled trial was to evaluate the effect of inhaled GSH in patients with CF.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Cyst. Fibros.

Title: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

ISSN (Electronic): 1873-5010

ISSN (Print): 1569-1993

Publication date (Electronic): Mar 2015

Volume: 14

Issue: 2

Affiliations

[1 ] Department of Cardiothoracic and Respiratory Sciences, Second University of Naples, Italy.

[2 ] Department of Translational Medical Sciences, Cystic Fibrosis Center, University "Federico II" of Naples, Italy.

[3 ] Department of Pediatrics, Cystic Fibrosis Center, Sapienza University of Rome, Italy.

[4 ] Pediatric Pneumology, Santobono-Pausilipon-Annunziata Children's Hospital, Naples, Italy.

[5 ] Department of Translational Medical Sciences, Cystic Fibrosis Center, University "Federico II" of Naples, Italy. Electronic address: raia@unina.it.

Article

Publisher Item ID: S1569-1993(14)00226-4

DOI: 10.1016/j.jcf.2014.09.014

PubMed ID: 25458463

SO-VID: aab6c9e0-1e51-418f-b090-a1ead0d9964e

History

Keywords: Cystic fibrosis,Glutathione,Therapy

Data availability:

Keywords: Cystic fibrosis, Glutathione, Therapy

Comments

Comment on this article

scite_

Cited by 9

See all cited by

- Version 1